Holders — by stockHoldings — by fund
Casdin Capital, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001534261
$2.00B
disclosed book value
43
positions
24.2%
largest position share
Positions, as of 2026-06-30
top 43 of 43 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | RVMDREVOLUTION MEDICINES INC | 2.6M | $482.7M | 24.2% |
| 2 | RLAYRELAY THERAPEUTICS INC | 16.0M | $300.0M | 15% |
| 3 | WGSGENEDX HOLDINGS CORP | 3.7M | $254.5M | 12.7% |
| 4 | BLFSBIOLIFE SOLUTIONS INC | 4.7M | $131.5M | 6.6% |
| 5 | ILMNILLUMINA INC | 530,000 | $93.2M | 4.7% |
| 6 | LABSTANDARD BIOTOOLS INC | 88.8M | $73.0M | 3.7% |
| 7 | GPCRSTRUCTURE THERAPEUTICS INC | 1.2M | $63.1M | 3.2% |
| 8 | DNLIDENALI THERAPEUTICS INC | 2.0M | $52.6M | 2.6% |
| 9 | NGNENEUROGENE INC | 1.5M | $48.6M | 2.4% |
| 10 | BEAMBEAM THERAPEUTICS INC | 1.4M | $46.3M | 2.3% |
| 11 | TXG10X GENOMICS INC | 1.1M | $40.3M | 2% |
| 12 | SRRKSCHOLAR ROCK HLDG CORP | 665,000 | $36.6M | 1.8% |
| 13 | PSNLPERSONALIS INC | 2.5M | $34.2M | 1.7% |
| 14 | GRALGRAIL INC | 480,000 | $32.8M | 1.6% |
| 15 | GHGUARDANT HEALTH INC | 185,000 | $27.8M | 1.4% |
| 16 | MAZEMAZE THERAPEUTICS INC | 843,857 | $25.2M | 1.3% |
| 17 | HIMSHIMS & HERS HEALTH INC | 700,000 | $24.3M | 1.2% |
| 18 | ALNYALNYLAM PHARMACEUTICALS INC | 75,000 | $22.6M | 1.1% |
| 19 | TSHATAYSHA GENE THERAPIES INC | 3.3M | $22.1M | 1.1% |
| 20 | AGMBAGOMAB THERAPEUTICS NV | 1.6M | $20.1M | 1% |
| 21 | SEPNSEPTERNA INC | 553,268 | $18.5M | 0.9% |
| 22 | PBLSPARABILIS MEDICINES INC | 645,690 | $17.7M | 0.9% |
| 23 | SIONSIONNA THERAPEUTICS INC | 400,000 | $17.6M | 0.9% |
| 24 | VCYTVERACYTE INC | 276,308 | $16.2M | 0.8% |
| 25 | ANLADLAI NORTYE LTD | 1.3M | $14.4M | 0.7% |
| 26 | PRMEPRIME MEDICINE INC | 3.2M | $11.7M | 0.6% |
| 27 | ABSIABSCI CORPORATION | 973,260 | $11.3M | 0.6% |
| 28 | DGXQUEST DIAGNOSTICS INC | 50,000 | $10.6M | 0.5% |
| 29 | SRPTSAREPTA THERAPEUTICS INC | 470,000 | $8.4M | 0.4% |
| 30 | UNIQURE NV | 150,000 | $6.9M | 0.3% |
| 31 | NTLAINTELLIA THERAPEUTICS INC | 355,000 | $6.0M | 0.3% |
| 32 | MRNAMODERNA INC | 75,000 | $5.3M | 0.3% |
| 33 | IRONDISC MEDICINE INC | 65,000 | $4.8M | 0.2% |
| 34 | GLUEMONTE ROSA THERAPEUTICS INC | 186,014 | $4.5M | 0.2% |
| 35 | IPSCCENTURY THERAPEUTICS INC | 1.2M | $3.0M | 0.2% |
| 36 | CTNMCONTINEUM THERAPEUTICS INC | 148,333 | $2.4M | 0.1% |
| 37 | BBOTBRIDGEBIO ONCOLOGY THERAPEUT | 282,312 | $2.2M | 0.1% |
| 38 | EDITEDITAS MEDICINE INC | 445,000 | $1.4M | 0.1% |
| 39 | PACBPACIFIC BIOSCIENCES CALIF IN | 723,767 | $1.2M | 0.1% |
| 40 | KARDKARDIGAN INC | 50,000 | $1.2M | 0.1% |
| 41 | RXRXRECURSION PHARMACEUTICALS IN | 165,323 | $606,735 | 0% |
| 42 | DNAGINKGO BIOWORKS HOLDINGS INC | 36,493 | $361,646 | 0% |
| 43 | TNYATENAYA THERAPEUTICS INC | 361,969 | $267,531 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.